MOTS-c vs Mazdutide

MOTS-c and Mazdutide represent divergent strategies in metabolic peptide research. MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) that functions as an endogenous metabolic regulator, discovered in 2015 from the mitochondrial 12S rRNA gene. Its research has primarily been conducted in preclinical models, with a focus on insulin sensitivity, exercise mimetic effects, and age-related metabolic decline. In contrast, Mazdutide is a synthetic dual GLP-1/glucagon receptor agonist (MW ~4233.7 g/mol) developed by Innovent Biologics and Eli Lilly, which received its first regulatory approval in China in June 2024 for chronic weight management. Mazdutide's evidence base includes Phase III clinical trials, whereas MOTS-c has only completed a Phase 1 trial of a modified analog (CB4211). This comparison highlights key differences in mechanism, evidence maturity, and research applications.

MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered by Lee et al. at the University of Southern California in 2015, it acts as a metabolic regulator primarily through AMPK activation. In preclinical mouse models, MOTS-c has been shown to prevent diet-induced obesity and insulin resistance, enhance exercise capacity—with old mice running 2× longer on treadmill tests—and reduce age-related metabolic decline. These findings suggest a role in improving insulin sensitivity, glucose metabolism, and energy homeostasis. A modified analog, CB4211, demonstrated good tolerability in a Phase 1 human trial, but no clinical trials of native MOTS-c have been completed. Thus, while preclinical evidence is promising, human data remain absent, limiting translational certainty.

Mazdutide (IBI362) is a once-weekly injectable dual GLP-1/glucagon receptor agonist. By activating both receptors, it aims to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. This dual mechanism positions it as a candidate for weight management and glycemic control. Mazdutide was approved in China in June 2024 for chronic weight management, marking the first regulatory approval of a dual GLP-1/glucagon agonist globally. Phase III trials in China for type 2 diabetes are ongoing. Clinical evidence demonstrates significant weight loss in Chinese adults with obesity, effective glycemic control, and reductions in hepatic fat content. The evidence base is robust, with multiple completed and ongoing clinical trials supporting its efficacy and safety.

Both MOTS-c and Mazdutide are studied for metabolic health, but their research contexts differ. MOTS-c is primarily investigated in preclinical models for metabolic regulation, with additional research into anti-aging mechanisms such as mitochondrial function and exercise mimetic effects. Mazdutide, with its clinical approval, is more directly applied to weight management and glycemic control in human populations. While both target metabolic pathways, MOTS-c research focuses on fundamental mitochondrial signaling and age-related decline, whereas Mazdutide research emphasizes clinical outcomes like weight loss and hepatic fat reduction. Researchers should consider these distinct applications when selecting a peptide for specific study objectives.

Safety profiles for MOTS-c and Mazdutide reflect their different stages of research. For MOTS-c, no adverse effects have been reported in preclinical animal studies, but human tolerability for the native peptide is completely unknown due to the absence of completed human trials. The modified analog CB4211 showed good tolerability in a Phase 1 trial, providing some indirect safety data. For Mazdutide, common side effects are gastrointestinal, including nausea, vomiting, and diarrhea, which are dose-dependent and generally transient. These are consistent with the GLP-1 agonist class. Additionally, a heart rate increase has been observed, also typical of GLP-1 agonists. Researchers should weigh the limited human safety data for MOTS-c against the well-characterized but class-typical side effects of Mazdutide.